tbuckley/cabot-search huggingface dataset:
Multiple organ dysfunction syndrome in bone marrow transplantation
Authors: W. D. Haire
Journal: JAMA (1995)

<h3>Objective.</h3> —To define the frequency and outcome of organ dysfunction in bone marrow transplantation (BMT) and to determine if patients with organ dysfunction have lower levels of protein C (PC) and/or antithrombin III (ATIII) than those without organ dysfunction. <h3>Design.</h3> —Inception cohort of patients undergoing BMT, followed for 28 days, until hospital dismissal, or until death. <h3>Setting.</h3> —Bone marrow transplant department of a university hospital. <h3>Patients.</h3> —A total of 199 consecutive patients admitted for BMT. <h3>Interventions.</h3> —Standard supportive care was given to all patients. <h3>Main Outcome Measures.</h3> —Definitions of organ dysfunction were arrived at prior to beginning the study. They include pulmonary, central nervous system (CNS), hepatic, and renal dysfunction. Protein C and ATIII levels were measured prior to beginning the preparative regimen and weekly thereafter. <h3>Results.</h3> —Single organ dysfunction, manifesting as pulmonary, CNS, or hepatic dysfunction, occurred in 93 (48.5%) of the 199 patients and was a strong predictor of multiple organ dysfunction syndrome (MODS) and death. Death occurred in 14 (7.0%) of the patients. Cause of death was precisely identified in only four patients. Low levels of either PC or ATIII were associated with death and pulmonary, CNS, and hepatic dysfunction. Multivariate analysis showed ATIII and PC levels were associated with single organ dysfunction independent of the type of transplant, the type of preparative regimen, and the presence of bacteremia. <h3>Conclusions.</h3> —Single organ dysfunction during BMT is a marker for a systemic abnormality that has a high likelihood of progressing to MODS, similar to that seen in other critically ill patient populations. MODS is the leading cause of death in series of BMT patients. Low levels of ATIII and PC are markers of and may be involved in the pathogenesis of MODS in BMT. (<i>JAMA</i>. 1995;274:1289-1295)
Correction: The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group
Journal: Clinical Cancer Research (2011)

published in the September 1, 2010 issue of Clinical Cancer Research (1), there is a minor error in Table 2.In cohorts where some patients were missing data on Gleason grade, these patients were added in error to the "Gleason 8" total.For example, in the SABOR cohort, there were 3 patients with missing Gleason grade and so the number for patients with Gleason 8 is reduced by 3, from 10 to 7.The corrected values are as follows:The authors can confirm that the correct numbers for Gleason 8þ tumors were used in all subsequent analyses and that, as such, their conclusions are unaffected.
Study Group Member Omitted.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
Authors: Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuelsz, Mark G. Erlander, Tanios S. Bekaii-Saab, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2020)

TPS4116 Background: Chemotherapy in combination with targeted agents are standard-of-care options for patients for mCRC with response rates &gt;50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower with response rates of 5% for FOLFIRI (5-fluorouracil, leucovorin, irinotecan) + bevacizumab (anti-VEGF). New treatment options are urgently needed in particular for the 50 % of patients harboring a KRAS mutation. PLK1 is a serine/threonine kinase, master regulator of the mitotic checkpoint and cell division. PLK1 is overexpressed in CRC and its overexpression is associated with poor prognostic. A genome wide RNAi screen identified PLK1 as a synthetic lethal target in KRAS mutant CRC cells, inducing cell cycle arrest and apoptosis upon inhibition. Onvansertib is an oral, highly selective PLK1 inhibitor that demonstrates single agent and synergistic activity with irinotecan in preclinical CRC models. Additionally, KRAS mutated vs wild-type cells showed higher sensitivity to onvansertib. PLK1 inhibition is a potential target in KRAS-mutated mCRC, and the combination of onvansertib + FOLFIRI + bevacizumab may provide a new second-line treatment option. Methods: The primary objective of this single-arm Phase 1b/2 study is to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab in the second line setting for KRAS-mutated mCRC patients. For the Phase 1b segment, a standard 3 + 3 dose-escalation design is used to determine the maximum tolerated dose or recommended phase 2 dose (RP2D) of onvansertib. As of January 24, 2020, enrollment in the second dose level is ongoing. Efficacy will be determined by objective response rate (ORR) according to RECIST v1.1 (primary endpoint), progression-free survival and reduction in KRAS allelic burden in liquid biopsies (secondary endpoints). In the phase 2, based on a one-sided one sample log-rank test with 10% Type I error, there will be at least 90% power to detect an improvement in ORR from 5% to 20% with 26 patients. Exploratory endpoints include genomic studies of circulating tumor cells and ctDNA to evaluate altered pathways that correlate with patient clinical response. Clinical trial information: NCT03829410 .
Is the renin-sodium profile helpful in evaluating hypertension?
Authors: R. W. Gifford
Journal: JAMA (1980)

LARAGH and colleagues<sup>1</sup>have long advocated measurement of plasma renin activity (PRA) routinely in the evaluation of hypertensive patients. They have presented an elaborate and somewhat complicated schema for using the PRA as an aid in diagnostic evaluation and in selecting drugs. Reliable measurements of PRA are not readily available to many physicians, and when they are, care must be taken to control, so far as is possible, those variables that influence PRA, such as physical activity, normal diurnal variations, drugs (eg, estrogens, diuretics, and antihypertensive agents), and sodium intake. Laragh et al recommend that blood be drawn at the same time of day (noon), after the patient has been ambulatory for several hours, and that the urinary sodium excretion for the previous 24 hours be measured to estimate the state of sodium balance. Does the information provided by a renin-sodium profile justify this meticulous attention to detail and the
Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features
Authors: Abdel Kareem Azab, Jinsong Hu, Phong Quang, Feda Azab, Costas Pitsillides, Brian Thompson, Patricia Maiso, Aldo M Roccaro, Antonio Sacco, Hai T Ngo, Ghayas C. Issa, Charles Lin, Andrew L. Kung, Karin Vanderkerken, Irene M. Ghobrial
Journal: Blood (2011)
TMIC-41. LOSS OF HOST-DERIVED OSTEOPONTIN CREATES A GLIOBLASTOMA-PROMOTING MICROENVIRONMENT
Authors: Frank Szulzewsky, Nina Schwendinger, Dilansu Güneykaya, Patrick Cimino, Dolores Hambardzumyan, Michael Synowitz, Eric Holland, Helmut Kettenmann
Journal: Neuro-Oncology (2017)

Microglia and periphery-derived monocytes infiltrate human and mouse glioblastoma and their density is positively correlated with malignancy. Using microarray and RNA sequencing we have previously shown that glioblastoma-associated microglia/monocytes (GAMs) express osteopontin/OPN. We used qRT-PCR, immunofluorescence stainings, western blot, and flow cytometry to identify the various sources of OPN expression in human and mouse glioblastoma. We implanted wild type GL261 glioblastoma cells, which do not express significant levels of OPN, into wild-type and OPN-/- mice to investigate the role of microenvironment-derived OPN on glioblastoma progression. Our data indicates that GAMs are the predominant source of OPN in both human and mouse glioblastoma and only express the secreted form of OPN. Loss of microenvironment-derived OPN enhanced tumor progression. Ki67 and TUNEL staining showed no difference in overall cell proliferation but a decreased apoptosis rate in tumors in OPN-/- mice. CD31 staining showed a significantly decreased number of microvessels in tumors in OPN-/- mice, accompanied by reduced coverage of vessels with PDGFRβ-positive pericytes. Flow cytometry analysis revealed a significant increase of CD11b+/CD45low microglia but not of CD11b+/CD45high macrophages/monocytes in tumors in OPN-/- mice. Sorted CD11b+ cells from wild type and OPN-/- naïve brains and tumors did not show a significant difference in the expression pattern of activation marker genes. Our results show that in human and mouse glioblastoma OPN is predominantly expressed and secreted by GAMs and that – in contrast to OPN expression in the tumor cells per se – loss of stroma-derived OPN creates a glioblastoma-promoting microenvironment.
Consultants for The Journal in 1964
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improved Prospects for Long-term Survival in Adults With Acute Myelogenous Leukemia
Authors: M. J. Keating, K. B. McCredie, G. P. Bodey, T. L. Smith, E. Gehan, E. J Freireich
Journal: JAMA (1982)

An improved complete remission rate in acute myelogenous leukemia (AML) has been noted since cytarabine and anthracyclines were introduced into clinical practice. Forty-one (9%) of 457 patients with AML treated between 1965 and 1976 have survived more than five years. The proportion of five-year survivors for patients treated between 1973 and 1976, 1970 and 1972, and 1965 and 1969 were 11.8%, 8.8%, and 1.8%, respectively. The major factor influencing five-year survival was whether or not patients were treated with cytarabine alone or combined with an anthracycline. Thirty-six (17%) of the 207 complete responders remained in continuous complete remission for more than five years. Twenty-four of the 36 patients who are in remission for more than five years have not been receiving chemotherapy for more than five years and are considered potentially cured. (<i>JAMA</i>1982;248:2481-2486)
Error in Abstract
Authors: Neena Modi, Cheryl Battersby, Bmedsci Longford
Journal: JAMA Pediatrics (2017)

J. Dennis Fortenberry, MD, MS; Linda J. Koenig, PhD; Bill G. Kapogiannis, MD; Carrie L. Jeffries, RN, MPH; Jonathan M. Ellen, MD; Craig M. Wilson, MD
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab.
Authors: Marcello Tiseo, Michele Veneziani, Francesco Gelsomino, Sebastiano Buti, Francesco Facchinetti, Anna Squadrilli, Paola Bordi, Melissa Bersanelli, Agnese Cosenza, Leonarda Ferri, Elena Rapacchi, Giulia Mazzaschi, Francesco Leonardi, Federico Quaini, Andrea Ardizzoni, Gabriele Missale
Journal: Journal of Clinical Oncology (2017)

e14514 Background: Detection of predictive markers of anti-PD-1/PD-L1 antibodies activity is of pivotal interest in non-small cell lung cancer (NSCLC). This study aimed to identify a circulating immuno-profile as predictor of outcome in NSCLC patients treated with nivolumab Methods: A peripheral blood immuno-profile evaluation was performed at baseline (T0), after 2 (T1) and 4 cycles (T2) of bi-weekly nivolumab in advanced pre-treated NSCLC patients from two Italian Institutions. First tumor assessment was performed after 4 cycles and then every 2 months. FACS analysis of lymphocyte subpopulations [CD3, CD4, CD8, NK (CD56), Treg (FOXP3) and MDSC] was performed. Absolute and % changes of lymphocyte subsets together with their functional and proliferative activity were assessed. Quali-quantitative leucocyte composition at baseline and its variation during therapy were correlated with tumor response and survival. Results: In the overall population of 54 treated patients, baseline Neutrophil-to-Lymphocyte ratio and NK count, lymphocyte count and CD4 variations during therapy showed a statistically significant prognostic role (p &lt; 0.001; p = 0.012; p &lt; 0.001; p = 0.010, respectively). Among 31 patients (squamous carcinoma, n = 17; adenocarcinoma, n = 14) in which all 3 time-points samples were available, 19 were responders (response and stable disease) and 12 non-responders. In responders, absolute numbers of total NK and NKCD56dim subset were higher at baseline and their increase between T0 and T1 was statistically significant (p &lt; 0.05). Responders also displayed increased cytotoxic capability as shown by a higher baseline expression of CD3ζ, perforin and granzyme in NKCD56dim subset. No significant variation was documented in absolute number and functional activity of CD4+ and CD8+ lymphocytes. A higher percentage of CD8+PD-1+ cells at baseline was observed in responders, while non-responders showed a statistically significant increase in the absolute number of MDSC during therapy (p &lt; 0.05). Conclusions: The number and function of NKs and the frequency of PD-1 expression in CD8+ cells could represent predictive peripheral immuno-biomarkers for nivolumab treatment in advanced NSCLC.
Hypothermia in the treatment of acute pancreatitis. Report of two cases
Authors: S. A. Roddenbery
Journal: JAMA (1967)

A hypothermic unit was used to reduce and control extreme hyperpyrexia in two patients with acute pancreatitis. Both survived. Recent experiences by others using hypothermia in the treatment of experimental pancreatitis give us a rational explanation for the good response in both patients. The encouraging results obtained with a hypothermic unit as a basic therapeutic modality in severe cases of pancreatitis warrant additional clinical trials.
FEDERAL PROTECTION OF THE PUBLIC HEALTH.
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OCCLUSION OF THE RIGHT POSTEROINFERIOR CEREBELLAR ARTERY
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL EQUIPMENT OF WARSHIPS.
Journal: JAMA (1904)

The Russo-Japan war is likely to give us some additional points in regard to military medicine. The Japanese have shown themselves to be good scientific observers, and it will not be irrational to suppose that there are also equally competent ones in the Russian service. One rather important suggestive point has already been brought out by the report of Dr. H. D. Wilson of the gunboat<i>Vicksburg</i>in regard to the wounded in naval warfare. He was sent to aid in the care of the wounded of the<i>Variag</i>after her first engagement with the Japanese fleet and reports that notwithstanding the fact that the ships did not come into close contact and only the main batteries were used, the number of wounded on board that ship, well fitted as she was to care for the ordinary emergencies as it was supposed, proved her arrangements for medical and surgical care
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer
Authors: Valerie W. Rusch, John Crowley, Dorothy J. Giroux, Peter Goldstraw, Jung-Gi Im, Masahiro Tsuboi, Ryosuke Tsuchiya, Johan Vansteenkiste
Journal: Journal of Thoracic Oncology (2007)
Thank You, Lancaster Press
Authors: J. R. E.
Journal: Annals of Internal Medicine (1969)

Editorials1 December 1969Thank You, Lancaster PressJ. R. E., E. J. H.J. R. E.Search for more papers by this author, E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-71-6-1214 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough the Annals of Internal Medicine has been printed by the Lancaster Press of Lancaster, Pa., for almost four decades, this is the last issue to be so printed; the January issue will be printed by another company. The reasons for this change stem from the growth of our circulation and the increased needs for speed in publication and precision in meeting schedules. Part of the answer to these needs would seem to lie in the use of photo-offset, rather than letterpress, printing. Sadly, therefore, the ANNALS and Lancaster Press end their joint endeavor.In printing the ANNALS, Lancaster has... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1969Volume 71, Issue 6Page: 1214-1215 ePublished: 1 December 2008 Issue Published: 1 December 1969 PDF downloadLoading ...
Coming Society Meetings
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antioxidant Supplementation Prevents Oxidation and Inflammatory Responses Induced by Sidestream Cigarette Smoke in Old Mice
Authors: Jin Zhang, Shuguang Jiang, Ronald R. Watson
Journal: Environmental Health Perspectives (2001)

Sidestream cigarette smoke (SSCS) makes up about 85% of significantly toxic environmental tobacco smoke (ETS). Reactive oxygen species (ROS) in SSCS play an important role in the pathogenesis of a wide range of diseases. Interleukin-6 is a pro-inflammatory cytokine and is closely linked with pathology in cardiovascular disease and conditions that have an inflammatory base. Exposure to SSCS through a burning cigarette for 30 min/day, 5 days a week, for 4 months increased interleukin-6 production in spleen and lipid peroxide level in mouse liver. Our findings suggest that ROS induced by SSCS will promote hepatic lipid peroxidation and may also contribute to an increase in interleukin-6 cytokine production. Multiple antioxidants given as a dietary supplement significantly normalized interleukin-6 cytokine production and prevented hepatic lipid peroxidation. We conclude that the SSCS in moderate intake levels increased oxidation and promoted inflammatory cytokine interleukin-6 production, whereas antioxidants prevented these changes.